BioSpace News Archive

Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate achievements.

Coherus BioSciences, Inc., reported financial results for the quarter ended March 31, 2024 and recent business highlights.

Invivyd, Inc., a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, announced financial results for the quarter ended March 31, 2024, and recent business highlights.

Kronos Bio, Inc. reported recent business progress and financial results for the first-quarter of 2024.

Spyre Therapeutics, Inc. announced its first quarter 2024 financial results and provided program and corporate updates.

Avidity Biosciences, Inc. reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Biohaven Ltd. reported financial results for the first quarter ended March 31, 2024, and provided a review of recent accomplishments and anticipated upcoming developments.

Sangamo Therapeutics, Inc. today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced upcoming data presentations that highlight the company’s precision psychiatry pipeline and biomarker-based analyses at the Society of Biological Psychiatry (SOBP) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings, to take place May 9-11 in Austin, TX, and May 28-31 in Miami Beach, FL, respectively.

Alzamend Neuro, Inc. announced today that it has entered into a Securities Purchase Agreement (the “ Agreement ”) with an institutional investor (the “ Investor ”) for the purchase and sale of 50 shares of its Series A Convertible Preferred Stock.